COMP <GO>
EW vs LLY // FORWARD P/E MULTIPLE
Edwards Lifesciences Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EW 4
— LLY 11
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $92.01 (-2.57%) • MKT CAP: $54.44B
forward-pe
47.2x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EW VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EW | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.00% | 83.64% | -5.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.50% | 32.36% | -19.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.1x | 36.4x | -1.32 | EW | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 2.30% | +0.15 | EW | /fcf-yield <GO> |
| Operating Margin | 20.80% | 40.21% | -19.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 17.70% | 31.90% | -14.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 45.51% | -34.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.36 | 9.29 | +3.07 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 77.9 | -18.01 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | EW | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 47.2x | 26.3x | +20.95 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.44B | $1.33T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EW REV | LLY REV | EW GROSS % | LLY GROSS % | EW FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | $65.18B | 78.0% | 83.0% | $1.33B | $16.81B |
| FY 2024 | $5.44B | $45.04B | 79.5% | 81.3% | $289.9M | $8.82B |
| FY 2023 | $5.01B | $34.12B | 44.0% | 79.3% | $670.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EW // BETA 1.08
LLY // BETA 0.51